Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
On average, 15-20% of patients who have a TAVR aortic valve procedure end up needing a pacemaker as well. Here’s an explanation why, in plain…
Your access to the latest cardiovascular news, science, tools and resources.
The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk…
This week we review a report from Italy regarding the observation of RA disk thrombus formation in some patients following GORE Cardioform ASD closure. How…
Acute heart failure (AHF) has become a global public health burden largely because of the associated high morbidity, mortality, and cost. The treatment options for…
Voxelotor, which can help reduce need for blood transfusions, is administered as a daily tablet
The approval marks the return of the dissolving-scaffold concept, which so far has failed to find success in the coronaries.
Transcatheter aortic valve implantation (TAVI) has matured into a standard treatment option for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum…
Walmart had grand ambitions, back in 2019, to grow a network of cheaper primary care clinics attached to its ubiquitous stores. Those ambitions are now…
Amgen said that it will no longer develop an early-stage obesity pill, and will instead focus on an injectable candidate that’s seen as a potential…